WuXi PharmaTech Inc. and Open Monoclonal Technology, Inc. (OMT) have entered a second agreement to expand WuXi’s use of OMT’s OmniRat and OmniMouse technologies aimed at strengthening the development and commercial opportunities for WuXi’s Asian regional and global clients.
 
WuXi has duplicated the OmniRat platform at its Shanghai facility, allowing it to generate antibodies for customers from its own labs. WuXi’s clients can now choose to develop and commercialize products globally or regionally in China, Korea, Japan or other Asian territories. Clients that opt for regional rights can assume global rights prior to the first human dose. OMT retains the global product rights until and unless each option is exercised.
 
“This new agreement allows WuXi to further expand its service offerings with the OmniRat and OmniMouse platforms,” said Edward Hu, chief operating officer and chief financial officer of WuXi PharmaTech. “WuXi is proud of the confidence OMT has shown in the quality of WuXi’s antibody research capabilities and intellectual property protection practices in authorizing WuXi to host the OmniRat and OmniMouse platforms in our laboratories.”
 
Dr. Roland Buelow, founder and chief executive officer of OMT, said, “This second agreement with WuXi continues the global deployment of OMT’s human antibody technologies. The deal structure enables OMT to tap into the economics of rapidly growing Asian companies and, when global rights are not exercised by WuXi’s clients, to leverage their data for OMT product development and/or partnering outside Asia.”